<- Go Home
Otsuka Holdings Co., Ltd.
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement instruments, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, and insecticide and toiletry products. In addition, the company offers IT solution services; adhesive tapes; flaky titanate and compounds; IV solutions; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; urinary tract health products; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. Otsuka Holdings Co., Ltd. was founded in 1921 and is headquartered in Tokyo, Japan.
Market Cap
JPY 4.5T
Volume
1.1M
Cash and Equivalents
JPY 485.9B
EBITDA
JPY 454.6B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
JPY 1.5T
Profit Margin
70.66%
52 Week High
JPY 8.8K
52 Week Low
JPY 4.9K
Dividend
N/A
Price / Book Value
1.71
Price / Earnings
35.40
Price / Tangible Book Value
2.54
Enterprise Value
JPY 4.3T
Enterprise Value / EBITDA
8.86
Operating Income
JPY 353.6B
Return on Equity
5.10%
Return on Assets
6.34
Cash and Short Term Investments
JPY 485.9B
Debt
JPY 248.0B
Equity
JPY 2.7T
Revenue
JPY 2.2T
Unlevered FCF
N/A
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium